Pear Therapeutics

Redefining Medicine

Prescription Digital Therapeutics for the treatment of
serious disease

Watch the Video

Prescription Digital Therapeutics

Software to treat human disease

Prescription Digital Therapeutics, or PDTs, are software-based disease treatments. PDTs are designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. PDTs are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software.

Pear Therapeutics

The leader in Prescription Digital Therapeutics

At Pear, our mission is clear: we are pioneers in PDTs. Our cross-functional team operates at the intersection of biology and software technology. Pear discovers, develops, and delivers clinically validated software to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.

Our Pipeline

Multiple products, therapeutic areas, and development stages

We are developing prescription digital therapeutics to treat patients suffering from a range of serious diseases. Pear’s lead product, reSET®, works with face-to-face therapy to treat Substance Use Disorder, and was the first PDT to receive market authorization from the FDA to improve disease outcomes. Pear’s second product candidate, reSET-O® for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation and was authorized in December 2018. Our pipeline is focused on product candidates across development stages that demonstrate large, clinically relevant treatment effects.